Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.
V. Sandanayaka,B. Mamat,Rama K. Mishra,J. Winger,M. Krohn,Li-Ming Zhou,Monica Keyvan,L. Enache,D. Sullins,E. Onua,Jun Zhang,Gudrun V Halldorsdottir,Heida Sigthorsdottir,Audur Thorlaksdottir,G. Sigthorsson,Margret Thorsteinnsdottir,D. Davies,L. Stewart,D. Zembower,T. Andresson,A. Kiselyov,Jasbir Singh,M. Gurney
DOI: https://doi.org/10.1021/jm900838g
IF: 8.039
2010-01-28
Journal of Medicinal Chemistry
Abstract:Both in-house human genetic and literature data have converged on the identification of leukotriene 4 hydrolase (LTA(4)H) as a key target for the treatment of cardiovascular disease. We combined fragment-based crystallography screening with an iterative medicinal chemistry effort to optimize inhibitors of LTA(4)H. Ligand efficiency was followed throughout our structure-activity studies. As applied within the context of LTA(4)H inhibitor design, the chemistry team was able to design a potent compound 20 (DG-051) (K(d) = 26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke. The structural biology-chemistry interaction described in this paper provides a sound alternative to conventional screening techniques. This is the first example of a gene-to-clinic paradigm enabled by a fragment-based drug discovery effort.
Medicine